Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Modified Naples prognostic score for evaluating the prognosis of patients with obstructive colorectal cancer

Authors: Junnan Gu, Shenghe Deng, Zhenxing Jiang, Fuwei Mao, Yifan Xue, Le Qin, Jianguo Shi, Jia Yang, Huili Li, Jie Yu, Ke Liu, Ke Wu, Yinghao Cao, Kailin Cai

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Inflammatory, immune, and nutritional status are key factors in obstructive colorectal cancer (OCRC). This study aims to investigate the value of modified Naples prognostic score (M-NPS) in evaluating OCRC prognosis.

Methods

A total of 196 OCRC patients were retrospectively analyzed to construct M-NPS based on serum albumin (ALB), total cholesterol (CHOL), neutrophil:lymphocyte ratio (NLR), and lymphocyte:monocyte ratio (LMR), and then they were divided into three groups. The Kaplan–Meier (KM) method and Cox proportional hazard regression analysis were performed for overall survival (OS) and disease-free survival (DFS) of OCRC patients.

Results

Patients with high M-NPS had worse OS and DFS (P = 0.0001, P = 0.0011). Multivariate COX analysis showed that M-NPS was an independent prognostic factor for OCRC patients. Patients in the M-NPS 2 group had significantly worse OS (hazard ratio [HR] = 4.930 (95% confidence interval [95% CI], 2.217–10.964), P < 0.001) and DFS (HR = 3.508 (95% CI, 1.691–7.277), P < 0.001) than those in the 0 group.

Conclusion

M-NPS was an independent prognostic factor for OCRC patients; it might provide a potential reference for immunonutritional intervention in patients with obstruction.
Literature
1.
Kye BH, Lee YS, Cho HM, Kim JG, Oh ST, Lee IK, Kang WK, Ahn CH, Lee SC, Park JK, et al. Comparison of long-term outcomes between emergency surgery and bridge to surgery for malignant obstruction in right-sided Colon cancer: a Multicenter Retrospective Study. Ann Surg Oncol. 2016;23(6):1867–74.CrossRefPubMed
2.
Park YE, Park Y, Park SJ, Cheon JH, Kim WH, Kim TI. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. Surg Endosc. 2019;33(4):1225–34.CrossRefPubMed
3.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
4.
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503.CrossRefPubMed
5.
Lucas C, Barnich N, Nguyen HTT. Microbiota, inflammation and colorectal Cancer. Int J Mol Sci 2017, 18(6).
6.
Malka D, Lièvre A, André T, Taïeb J, Ducreux M, Bibeau F. Immune scores in colorectal cancer: where are we? Eur J Cancer. 2020;140:105–18.CrossRefPubMed
7.
Tokunaga R, Sakamoto Y, Nakagawa S, Miyamoto Y, Yoshida N, Oki E, Watanabe M, Baba H. Prognostic Nutritional Index predicts severe complications, recurrence, and poor prognosis in patients with Colorectal Cancer undergoing primary Tumor Resection. Dis Colon Rectum. 2015;58(11):1048–57.CrossRefPubMed
8.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81.CrossRefPubMed
9.
Yeo HL, Lee SW. Colorectal emergencies: review and controversies in the management of large bowel obstruction. J Gastrointest Surg. 2013;17(11):2007–12.CrossRefPubMed
10.
Reisinger KW, van Vugt JL, Tegels JJ, Snijders C, Hulsewé KW, Hoofwijk AG, Stoot JH, Von Meyenfeldt MF, Beets GL, Derikx JP, et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg. 2015;261(2):345–52.CrossRefPubMed
11.
Chan JC, Chan DL, Diakos CI, Engel A, Pavlakis N, Gill A, Clarke SJ. The lymphocyte-to-monocyte ratio is a Superior Predictor of overall survival in comparison to established biomarkers of Resectable Colorectal Cancer. Ann Surg. 2017;265(3):539–46.CrossRefPubMed
12.
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–72.CrossRefPubMedPubMedCentral
13.
Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–95.CrossRefPubMedPubMedCentral
14.
Fu Y, Chen X, Song Y, Huang X, Chen Q, Lv X, Gao P, Wang Z. The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer. BMC Cancer. 2021;21(1):792.CrossRefPubMedPubMedCentral
15.
Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Podzemny V, Castellano P, Orditura M, Napolitano V. Naples Prognostic score, based on Nutritional and Inflammatory Status, is an independent predictor of long-term outcome in patients undergoing surgery for Colorectal Cancer. Dis Colon Rectum. 2017;60(12):1273–84.CrossRefPubMed
16.
Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T, Kitagawa Y. Comparison of preoperative inflammation-based Prognostic Scores in patients with Colorectal Cancer. Ann Surg. 2018;267(3):527–31.CrossRefPubMed
17.
Guo D, Liu J, Li Y, Li C, Liu Q, Ji S, Zhu S. Evaluation of predictive values of Naples Prognostic score in patients with Unresectable Stage III Non-Small Cell Lung Cancer. J Inflamm Res. 2021;14:6129–41.CrossRefPubMedPubMedCentral
18.
Jin J, Wang H, Peng F, Wang X, Wang M, Zhu F, Xiong G, Qin R. Prognostic significance of preoperative Naples prognostic score on short- and long-term outcomes after pancreatoduodenectomy for ampullary carcinoma. Hepatobiliary Surg Nutr. 2021;10(6):825–38.CrossRefPubMedPubMedCentral
19.
Lieto E, Auricchio A, Tirino G, Pompella L, Panarese I, Del Sorbo G, Ferraraccio F, De Vita F, Galizia G, Cardella F. Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers (Basel) 2021, 13(18).
20.
Miyamoto Y, Hiyoshi Y, Daitoku N, Okadome K, Sakamoto Y, Yamashita K, Kuroda D, Sawayama H, Iwatsuki M, Baba Y, et al. Naples Prognostic score is a useful prognostic marker in patients with metastatic colorectal Cancer. Dis Colon Rectum. 2019;62(12):1485–93.CrossRefPubMed
21.
Boone K, Barber D, Brown B. Imaging with electricity: report of the european concerted action on Impedance Tomography. J Med Eng Technol. 1997;21(6):201–32.CrossRefPubMed
22.
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.CrossRefPubMed
23.
Chen XQ, Xue CR, Hou P, Lin BQ, Zhang JR. Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer. World J Gastroenterol. 2019;25(33):4970–84.CrossRefPubMedPubMedCentral
24.
Sato R, Oikawa M, Kakita T, Okada T, Abe T, Yazawa T, Tsuchiya H, Akazawa N, Sato M, Ohira T, et al. Preoperative change of modified Glasgow prognostic score after stenting predicts the long-term outcomes of obstructive colorectal cancer. Surg Today. 2020;50(3):232–9.CrossRefPubMed
25.
Sato R, Oikawa M, Kakita T, Okada T, Abe T, Yazawa T, Tsuchiya H, Akazawa N, Sato M, Ohira T, et al. The prognostic value of the prognostic nutritional index and inflammation-based markers in obstructive colorectal cancer. Surg Today. 2020;50(10):1272–81.CrossRefPubMed
26.
27.
28.
Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E, Taieb J. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol. 2014;20(14):3738–50.CrossRefPubMedPubMedCentral
29.
Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between Immune Landscapes, genetic subtypes and responses to Immunotherapy in Colorectal Cancer. Front Immunol. 2020;11:369.CrossRefPubMedPubMedCentral
30.
Fahim M, Dijksman LM, van Kessel CS, Smeeing DPJ, Braaksma A, Derksen WJM, Smits AB. Promising results of a new treatment in patients with bowel obstruction in colorectal surgery. Eur J Surg Oncol. 2020;46(3):415–9.CrossRefPubMed
31.
Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients 2019, 11(1).
32.
Fahim M, Dijksman LM, Derksen WJM, Bloemen JG, Biesma DH, Smits AB. Prospective multicentre study of a new bowel obstruction treatment in colorectal surgery: reduced morbidity and mortality. Eur J Surg Oncol. 2021;47(9):2414–20.CrossRefPubMed
33.
Mamtani R, Lewis JD, Scott FI, Ahmad T, Goldberg DS, Datta J, Yang YX, Boursi B. Disentangling the association between statins, cholesterol, and Colorectal Cancer: a nested case-control study. PLoS Med. 2016;13(4):e1002007.CrossRefPubMedPubMedCentral
Metadata
Title
Modified Naples prognostic score for evaluating the prognosis of patients with obstructive colorectal cancer
Authors
Junnan Gu
Shenghe Deng
Zhenxing Jiang
Fuwei Mao
Yifan Xue
Le Qin
Jianguo Shi
Jia Yang
Huili Li
Jie Yu
Ke Liu
Ke Wu
Yinghao Cao
Kailin Cai
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11435-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Study Protocol

Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study

Research

Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States

Research

Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma

Research

Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021

Research

Genetic and clinical landscape of ER + /PR- breast cancer in China

Research

New-onset dyslipidemia in adult cancer survivors from medically underserved areas: a 10-year retrospective cohort study

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits